Carisma Therapeutics – Harnessing the power of engineered macrophages
By engaging both the innate and adaptive immune systems to launch a multi-pronged attack on tumors, CAR-Macrophages address the key challenges faced by current cell therapies
Carisma develops novel adoptive cellular immunotherapies based on engineered macrophages with chimeric antigen receptors (CARs). The company’s first product is a HER2-targeting construct (CT-0508), which directs engineered macrophages to tissues overexpressing HER2, a well-known hallmark found in highly aggressive metastatic malignancies.
Industry
Therapeutics
